Choncept, L.L.C. (Choncept) is a privately held biotechnology company engaged in production and commercialization of chondroitin, a biopolymer used in ophthalmic applications and formulations with glucosamine for joint pain relief and strength. The company uses its proprietary technology to develop unsulfated chondroitin, through fermentation of recombinant bacteria, isolated from the animal sources. The modified chondroitin dermatan sulfate acts as an anti-coagulant and is utilized in pharmaceuticals and nutriceuticals. The company operates as a business unit of Emergent Technologies, Inc. and is also interested in developing partnership with other firms which would aid in the development of dermatan sulfate as an anti-coagulant. The company is headquartered at Oklahoma City in Oklahoma, the US.